Adalimumab: meta-analysis of COVID-19 studies

All studies   Mortality   Ventilation   ICU   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
c19early.org
October 2026

Adalimumab COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Fakharian (RCT)0%1.00 · 0.27–3.68death4/344/34
Late treatment0%1.00 · 0.27–3.684/344/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.27–3.684/344/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Adalimumab
reduces riskAdalimumab
increases risk →
c19early.org
October 2026

Adalimumab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Fakharian (RCT)0%1.00 · 0.27–3.684/344/34
Late treatment0%1.00 · 0.27–3.684/344/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.27–3.684/344/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Adalimumab
reduces riskAdalimumab
increases risk →
c19early.org
October 2026

Adalimumab COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Fakharian (RCT)−33%1.33 · 0.32–5.514/343/34
Late treatment−33%1.33 · 0.32–5.514/343/3433% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.7
All studies−33%1.33 · 0.32–5.514/343/3433% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.700.511.52+
Rotate screen for more detailsIncrease width for more details
← Adalimumab
reduces riskAdalimumab
increases risk →
c19early.org
October 2026

Adalimumab COVID-19 ICU results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Fakharian (RCT)0%1.00 · 0.32–3.145/345/34
Late treatment0%1.00 · 0.32–3.145/345/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.32–3.145/345/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Adalimumab
reduces riskAdalimumab
increases risk →
c19early.org
October 2026

Adalimumab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Fakharian (RCT)0%1.00 · 0.27–3.68death4/344/34
Late treatment0%1.00 · 0.27–3.684/344/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.27–3.684/344/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Adalimumab
reduces riskAdalimumab
increases risk →
c19early.org
October 2026

Adalimumab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Fakharian (RCT)0%1.00 · 0.27–3.68death4/344/34
Late treatment0%1.00 · 0.27–3.684/344/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.27–3.684/344/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Adalimumab
reduces riskAdalimumab
increases risk →
c19early.org
October 2026

Adalimumab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Fakharian (RCT)0%1.00 · 0.27–3.684/344/34
Late treatment0%1.00 · 0.27–3.684/344/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.27–3.684/344/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Adalimumab
reduces riskAdalimumab
increases risk →
c19early.org
October 2026

Adalimumab COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Fakharian (RCT)0%1.00 · 0.27–3.68death4/344/34
Late treatment0%1.00 · 0.27–3.684/344/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.27–3.684/344/340% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Adalimumab
reduces riskAdalimumab
increases risk →